The ILIAS ANOCA randomized trial shows that routine invasive coronary function testing (CFT) during angiography in patients with angina and non‑obstructive coronary arteries (ANOCA) is feasible, safe, yields a high diagnostic rate of vasomotor disorders (78%), and—when disclosed with a tailored treatment protocol—produces a clinically meaningful improvement in angina-related quality of life at 6 months.